Meissa's Positive Clinical Data for the First RSV Vaccine Designed to Protect Infants & Toddlers

Meissa Vaccines Enters into CGMP Manufacturing Agreement for Pediatric RSV Vaccine Candidate

Meissa's Positive Interim Clinical Data for Its Intranasal Live Attenuated RSV Vaccine for Infants

Meissa Vaccines Presented at The White House Summit on the Future of COVID-19 Vaccines

Meissa Vaccines Appoints Frank Glavin Chief Executive Officer

The Scientist: Nasal Vaccines Are Commercially High Risk, Perhaps High Reward